InvestorsHub Logo

Investor100

02/24/12 9:21 AM

#52065 RE: Investor100 #52060

CHTP:FDA Advisory Panel Recommends Approval of Chelsea's NORTHER(TM) (droxidopa) for the Treatment of Symptomatic Neurogenic OH

CHARLOTTE, N.C., Feb. 23, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP - News) today announced that the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 7-4 with 1 abstention and 1 non-vote to recommend approval of NORTHERA(TM) (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (also known as Neurogenic OH or NOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

Deutsche Bank Sees Upside in Chelsea Therapeutics (CHTP) to $9 On FDA Approval
http://www.streetinsider.com/Analyst+Comments/Deutsche+Bank+Sees+Upside+in+Chelsea+Therapeutics+%28CHTP%29+to+%249+On+FDA+Approval/7210845.html

http://finance.yahoo.com/news/FDA-Advisory-Panel-Recommends-pz-1041433021.html?x=0

Investor 100